share_log

Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $34.78

Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $34.78

Synairgen(伦敦股票代码:SNG)股价跌破200日移动均线34.78美元
Defense World ·  2022/08/27 03:01

Synairgen plc (LON:SNG – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 34.78 ($0.42) and traded as low as GBX 21.08 ($0.25). Synairgen shares last traded at GBX 22 ($0.27), with a volume of 146,989 shares trading hands.

在周五的交易中,Synairgen plc(伦敦股票代码:SNG-GET Rating)的股价跌破了200日移动均线。该股的200日移动均线为34.78英镑(合0.42美元),最低交易价格为21.08英镑(合0.25美元)。Synairgen的股票最新报22英镑(0.27美元),总成交量为146,989股。

Synairgen Price Performance

Synairgen性价比

The company has a current ratio of 5.82, a quick ratio of 5.69 and a debt-to-equity ratio of 0.09. The firm has a market cap of £44.30 million and a P/E ratio of -0.91. The company has a fifty day moving average price of GBX 27.53 and a two-hundred day moving average price of GBX 34.78.

该公司的流动比率为5.82,速动比率为5.69,债务权益比率为0.09。该公司的市值为4430万GB,市盈率为-0.91。该公司的50日移动平均价为27.53英镑,200日移动平均价为34.78英镑。

About Synairgen

关于Synairgen

(Get Rating)

(获取评级)

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.

Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有:治疗新冠肺炎的乙型吸入型干扰素SG001;治疗感冒和流感引起的哮喘的乙型干扰素吸入剂;治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验;以及治疗特发性肺纤维化的LXL2抑制剂。

Featured Articles

专题文章

  • Why This Dip in Advanced Auto Parts May be an Opportunity
  • MarketBeat: Week in Review 8/22 – 8/26
  • Institutional Buying Put A Bottom In Marvell Technology
  • Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
  • 3 Reasons Dollar General's Rally Has Legs
  • 为什么进军高级汽车零部件可能是一个机会
  • MarketBeat:回顾中的一周8/22-8/26
  • 机构买入让Marvell科技陷入低谷
  • 戴尔股票因销售疲软而回落,跌入可怕的价值
  • Dollar General的拉力赛有三个理由

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.

接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发